Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis

(2022) Maëlle Chappuis et al.   JOURNAL OF NEUROLOGY

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

(2022) Izanne Roos et al.   NEUROLOGY

Diagnosis and Treatment of Multiple Sclerosis

(2021) Marisa P. McGinley et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

(2021) Jordi Río et al.   JOURNAL OF NEUROLOGY

Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US

(2021) Lilyana Amezcua et al.   JAMA Neurology

Prescribing of disease modifying agents in older adults with multiple sclerosis

(2021) Ashna Talwar et al.   Multiple Sclerosis and Related Disorders

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

(2020) Gabriel Bsteh et al.   EUROPEAN JOURNAL OF NEUROLOGY

FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patients

(2019) Jagannadha Avasarala   CNS SPECTRUMS

The prevalence of MS in the United States

(2019) Mitchell T. Wallin et al.   NEUROLOGY

Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis

(2019) Finja Schweitzer et al.   CURRENT OPINION IN NEUROLOGY

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies

(2019) Marisa P McGinley et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes

(2019) Hajime Yano et al.   Multiple Sclerosis and Related Disorders

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

(2018) Ilya Kister et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains

(2016) R. Green et al.   Applied Neuropsychology-Adult

A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity

(2015) Mariana López-Góngora et al.   BMC Neurology

Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials

(2015) A. Signori et al.   EUROPEAN JOURNAL OF NEUROLOGY

Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening

(2014) Glenn A Phillips et al.   Multiple Sclerosis Journal

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Relapses in multiple sclerosis are age- and time-dependent

(2008) H Tremlett et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY